Cargando…
The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer
The management of Stage III non-small cell lung cancer (NSCLC) is complex and requires multidisciplinary input. Since the publication of the PACIFIC trial (consolidative durvalumab post concurrent chemotherapy and radiation in Stage III disease) which showed improved survival for patients in the imm...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700596/ https://www.ncbi.nlm.nih.gov/pubmed/34940090 http://dx.doi.org/10.3390/curroncol28060451 |
_version_ | 1784620795223343104 |
---|---|
author | Perdrizet, Kirstin Cheema, Parneet K. |
author_facet | Perdrizet, Kirstin Cheema, Parneet K. |
author_sort | Perdrizet, Kirstin |
collection | PubMed |
description | The management of Stage III non-small cell lung cancer (NSCLC) is complex and requires multidisciplinary input. Since the publication of the PACIFIC trial (consolidative durvalumab post concurrent chemotherapy and radiation in Stage III disease) which showed improved survival for patients in the immunotherapy arm, there has been much interest in the use of immunotherapy in the Stage III setting. In this review, we explore the biologic and clinical rationale for the use of immunotherapy in Stage III NSCLC, present previously published and upcoming data in the neoadjuvant, adjuvant, and concurrent realms of Stage III management, and discuss unanswered questions and challenges moving forward. |
format | Online Article Text |
id | pubmed-8700596 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87005962021-12-24 The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer Perdrizet, Kirstin Cheema, Parneet K. Curr Oncol Review The management of Stage III non-small cell lung cancer (NSCLC) is complex and requires multidisciplinary input. Since the publication of the PACIFIC trial (consolidative durvalumab post concurrent chemotherapy and radiation in Stage III disease) which showed improved survival for patients in the immunotherapy arm, there has been much interest in the use of immunotherapy in the Stage III setting. In this review, we explore the biologic and clinical rationale for the use of immunotherapy in Stage III NSCLC, present previously published and upcoming data in the neoadjuvant, adjuvant, and concurrent realms of Stage III management, and discuss unanswered questions and challenges moving forward. MDPI 2021-12-16 /pmc/articles/PMC8700596/ /pubmed/34940090 http://dx.doi.org/10.3390/curroncol28060451 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Perdrizet, Kirstin Cheema, Parneet K. The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer |
title | The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer |
title_full | The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer |
title_fullStr | The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer |
title_full_unstemmed | The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer |
title_short | The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer |
title_sort | evolving role of immunotherapy in stage iii non-small cell lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700596/ https://www.ncbi.nlm.nih.gov/pubmed/34940090 http://dx.doi.org/10.3390/curroncol28060451 |
work_keys_str_mv | AT perdrizetkirstin theevolvingroleofimmunotherapyinstageiiinonsmallcelllungcancer AT cheemaparneetk theevolvingroleofimmunotherapyinstageiiinonsmallcelllungcancer AT perdrizetkirstin evolvingroleofimmunotherapyinstageiiinonsmallcelllungcancer AT cheemaparneetk evolvingroleofimmunotherapyinstageiiinonsmallcelllungcancer |